注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Aclaris Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于开发免疫炎症性疾病的候选药物。该公司专注于利用其在药物发现和开发以及激酶抑制方面的经验来开发小分子疗法,以帮助人们改善免疫炎症状况。其候选药物包括Zunsemetinib (ATI-450)、ATI-1777和ATI-2138。该公司的ATI-450是一种研究用的口服、小分子选择性MK2抑制剂化合物,用于治疗类风湿性关节炎。其ATI-1777是一种研究性局部用JAK 1/3抑制剂化合物,用于治疗特应性皮炎。该公司还致力于开发ATI-2138,一种研究性口服抑制剂化合物,是T细胞介导的自身免疫性疾病的潜在治疗方法。该公司还在开发口服肠道偏向JAK抑制剂,用来作为炎症性肠病的潜在治疗方法。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Neal S. Walker | 54 | 2012 | Co-Founder, President, Chairman & Interim CEO |
Marco Colonna | - | 2020 | Member of the Scientific Advisory Board |
Michael E. Weinblatt | - | 2020 | Member of the Scientific Advisory Board |
Philip J. Mease | - | 2021 | Member of Scientific Advisory Board |
Stanley B. Cohen | - | 2020 | Member of the Scientific Advisory Board |
James G. Krueger | - | 2020 | Member of the Scientific Advisory Board |
Christopher P. Molineaux | 58 | 2014 | Lead Independent Director |
Andrew Newman Schiff | 59 | 2017 | Independent Director |
Guy F. Webster | - | - | Member of Advisory Board |
Mark Bradshaw | 71 | - | Member of Advisory Board |
Leslie Baumann | - | - | Member of Advisory Board |
Pearl E. Grimes | - | - | Member of Advisory Board |
Klaus PJ Theobald | 68 | - | Member of Advisory Board |
Kenneth Beer | - | - | Member of Advisory Board |
William D. Humphries | 58 | 2016 | Independent Director |
Anand Mehra | 48 | 2014 | Independent Director |
James J. Leyden | 83 | - | Member of Advisory Board |
Bryan M. Reasons | 57 | 2018 | Independent Director |
Andrew L. Ondo | - | - | Member of Advisory Board |
Maxine Gowen | 66 | 2019 | Independent Director |
Andrew Kenneth Williams Powell | 66 | 2017 | Independent Director |
Vincent J. Milano | 60 | 2020 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核